guest ::
| Home > Publications database > Clinical translation of microbiome research. > print |
| 001 | 300347 | ||
| 005 | 20250423104621.0 | ||
| 024 | 7 | _ | |a 10.1038/s41591-025-03615-9 |2 doi |
| 024 | 7 | _ | |a pmid:40217076 |2 pmid |
| 024 | 7 | _ | |a 1078-8956 |2 ISSN |
| 024 | 7 | _ | |a 1546-170X |2 ISSN |
| 024 | 7 | _ | |a altmetric:176056658 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-00781 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Gilbert, Jack A |0 0000-0001-7920-7001 |b 0 |
| 245 | _ | _ | |a Clinical translation of microbiome research. |
| 260 | _ | _ | |a [New York, NY] |c 2025 |b Springer Nature |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1745397942_30950 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Apr;31(4):1099-1113 |
| 520 | _ | _ | |a The landscape of clinical microbiome research has dramatically evolved over the past decade. By leveraging in vivo and in vitro experimentation, multiomic approaches and computational biology, we have uncovered mechanisms of action and microbial metrics of association and identified effective ways to modify the microbiome in many diseases and treatment modalities. This Review explores recent advances in the clinical application of microbiome research over the past 5 years, while acknowledging existing barriers and highlighting opportunities. We focus on the translation of microbiome research into clinical practice, spearheaded by Food and Drug Administration (FDA)-approved microbiome therapies for recurrent Clostridioides difficile infections and the emerging fields of microbiome-based diagnostics and therapeutics. We highlight key examples of studies demonstrating how microbiome mechanisms, metrics and modifiers can advance clinical practice. We also discuss forward-looking perspectives on key challenges and opportunities toward integrating microbiome data into routine clinical practice, precision medicine and personalized healthcare and nutrition. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Azad, Meghan B |0 0000-0002-5942-4444 |b 1 |
| 700 | 1 | _ | |a Bäckhed, Fredrik |b 2 |
| 700 | 1 | _ | |a Blaser, Martin J |0 0000-0003-2447-2443 |b 3 |
| 700 | 1 | _ | |a Byndloss, Mariana |b 4 |
| 700 | 1 | _ | |a Chiu, Charles Y |0 0000-0003-2915-2094 |b 5 |
| 700 | 1 | _ | |a Chu, Hiutung |b 6 |
| 700 | 1 | _ | |a Dugas, Lara R |b 7 |
| 700 | 1 | _ | |a Elinav, Eran |0 P:(DE-He78)725ad944da4e1ea60389fe9dbbed2c7c |b 8 |u dkfz |
| 700 | 1 | _ | |a Gibbons, Sean M |0 0000-0002-8724-7916 |b 9 |
| 700 | 1 | _ | |a Gilbert, Katharine E |b 10 |
| 700 | 1 | _ | |a Henn, Matthew R |b 11 |
| 700 | 1 | _ | |a Ishaq, Suzanne L |0 0000-0002-2615-8055 |b 12 |
| 700 | 1 | _ | |a Ley, Ruth E |0 0000-0002-9087-1672 |b 13 |
| 700 | 1 | _ | |a Lynch, Susan V |0 0000-0001-5695-7336 |b 14 |
| 700 | 1 | _ | |a Segal, Eran |0 0000-0002-6859-1164 |b 15 |
| 700 | 1 | _ | |a Spector, Tim D |b 16 |
| 700 | 1 | _ | |a Strandwitz, Philip |b 17 |
| 700 | 1 | _ | |a Suez, Jotham |0 0000-0003-3836-972X |b 18 |
| 700 | 1 | _ | |a Tropini, Carolina |0 0000-0002-7542-1577 |b 19 |
| 700 | 1 | _ | |a Whiteson, Katrine |b 20 |
| 700 | 1 | _ | |a Knight, Rob |b 21 |
| 773 | _ | _ | |a 10.1038/s41591-025-03615-9 |0 PERI:(DE-600)1484517-9 |n 4 |p 1099-1113 |t Nature medicine |v 31 |y 2025 |x 1078-8956 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:300347 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)725ad944da4e1ea60389fe9dbbed2c7c |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2025-01-06 |w ger |
| 915 | _ | _ | |a DEAL Nature |0 StatID:(DE-HGF)3003 |2 StatID |d 2025-01-06 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-06 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT MED : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2025-01-06 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 80 |0 StatID:(DE-HGF)9980 |2 StatID |b NAT MED : 2022 |d 2025-01-06 |
| 920 | 1 | _ | |0 I:(DE-He78)D480-20160331 |k D480 |l Mikrobiom und Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D480-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|